• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Organigram Global Releases Landmark Report: Legal Cannabis Added $16B to Canada's GDP in 2024

    9/2/25 6:00:00 AM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OGI alert in real time by email

    New analysis shows cannabis as a national growth engine, aligning with Prime Minister Carney's One Canadian Economy vision.

    Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), Canada's largest cannabis company by market share, today released "High Impact, Green Growth: The Economic Footprint of Canada's Cannabis Industry," a national report done in partnership with the Business Data Lab at the Canadian Chamber of Commerce. The report, which examined figures for 2024, underscores the legal cannabis sector's role as a major driver of jobs, economic growth, and innovation, highlighting why it should be included as a pillar of Prime Minister Mark Carney's One Canadian Economy vision.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250902906425/en/

    The report shows that in 2024 Canada's legal cannabis industry contributed more than $16 billion to national GDP, generating nearly $29 billion in total economic output. To put its economic weight in perspective, cannabis's direct GDP contribution of $8.4 billion in 2024 exceeds that of forestry and logging ($3.4 billion), breweries ($2.6 billion), and wineries and distilleries ($975 million)1. The sector also supported over 227,000 jobs across the country, including 168,000 direct jobs in cultivation and retail, alongside 59,000 in supply, logistics and professional services. These contributions extend coast-to-coast, demonstrating cannabis's place as one of Canada's most significant homegrown industries.

    "The legal cannabis sector is a high-value industry that is already delivering what the Prime Minister's One Canadian Economy vision calls for: a nationally integrated, high-value industry that's built in Canada, employing Canadians, and competing globally," stated Beena Goldenberg, CEO of Organigram Global. "With bold national leadership, we can secure Canada's place as the world's cannabis leader; a driver of national economic resilience within the One Canadian Economy vision."

    Andrew DiCapua, Principal Economist with the Canadian Chamber of Commerce's Business Data Lab and author of High Impact, Green Growth, reinforced this point, noting:

    "Canada's legal cannabis industry has a major economic footprint in Canada. It is not only an emerging, domestic, sector that has created and sustained hundreds of thousands of jobs nationwide, but one with economic impacts felt coast-to-coast through the vast cannabis supply chain. This is precisely the type of industry that fits within the One Canadian Economy vision."

    While the report focuses on cannabis's overall economic footprint in 2024, its scale is striking when compared to traditional Canadian agricultural commodities. For example, legal cannabis is now New Brunswick's most valuable crop, with farm cash receipts hitting $269.4 million in 2022, more than potatoes and dairy2. According to Agriculture and Agri-Food Canada, between 2020 and 2024, cannabis has averaged about $232 million annually in farm receipts, further underscoring its key role as New Brunswick's leading agricultural product3. Nationally, cannabis generated $2.7 billion in farm cash receipts in 2024, outmatching greenhouse vegetables ($2.63 billion) and field vegetables ($2.44 billion)4.

    Yet, despite its outsized impact on Canada's economy last year, and the significant export potential of Canada's global first-mover advantage, outdated policy frameworks are preventing the sector from realizing its full potential. The current excise tax structure is designed around outdated pricing models, which limits innovation and growth. Moreover, the absence of a national export strategy is preventing Canada from capitalizing on an international cannabis market projected to surpass CAD $140 billion by 20265, putting Canada on the backfoot of export diversification and international market development.

    "We've built innovative, world-class cannabis production right here in Canada," concluded Ms. Goldenberg, "If Canada is serious about building the strongest economy in the G7, then industries like cannabis, which is already a $16 billion engine of jobs and innovation, must be a pillar of the One Canadian Economy strategy. It's time to modernize the rules, eliminate unnecessary barriers and unfair taxation, and give this industry the same opportunity to thrive as other strategic sectors."

    About Organigram

    Organigram Global Inc. is a NASDAQ Global Select Market and TSX listed company whose wholly owned subsidiary, Organigram Inc., is a licensed cultivator of cannabis and manufacturer of cannabis-derived goods in Canada. Through its acquisition of Collective Project Limited, Organigram Global participates in the U.S. and Canadian cannabinoid beverage markets.

    Organigram is focused on producing high-quality cannabis for adult consumers, as well as developing international business partnerships to extend the Company's global footprint. Organigram has also developed and acquired a portfolio of cannabis brands, including Edison, Big Bag O' Buds, SHRED, SHRED'ems, Monjour, Tremblant Cannabis, Collective Project, Trailblazer, BOXHOT and DEBUNK. Organigram operates facilities in Moncton, New Brunswick and Lac-Supérieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba. The Company also operates two additional cannabis processing facilities in Southwestern Ontario; one in Aylmer and the other in London. The facility in Aylmer houses best-in-class CO2 and Hydrocarbon extraction capabilities, and is optimized for formulation refinement, post-processing of minor cannabinoids, and pre-roll production. The facility in London will be optimized for labelling, packaging, and national fulfillment. The Company is regulated by Health Canada under the Cannabis Act and the Cannabis Regulations (Canada).

    Forward-Looking Information

    This news release contains forward-looking information. Often, but not always, forwardlooking information can be identified by the use of words such as "plans", "expects", "estimates", "intends", "anticipates", "believes" or variations of such words and phrases or state that certain actions, events, or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results, events, performance or achievements of Organigram to differ materially from current expectations or future results, performance or achievements expressed or implied by the forward-looking information contained in this news release.

    Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information include regulatory changes, consumer demand and preferences and factors and risks disclosed in the Company's most recent annual information form, management's discussion and analysis and other Company documents filed from time to time on SEDAR+ (see www.sedarplus.ca) and filed or furnished to the Securities and Exchange Commission on EDGAR (see www.sec.gov).

    Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this news release. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information included in this news release is made as of the date of this news release and the Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

    1 Statistics Canada. (2024). Gross domestic product (GDP) at basic prices, by industry, annual average, industry detail (Table 36-10-0434-06). Retrieved from https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=3610043406&pickMembers%5B0%5D=2.1&pickMembers%5B1%5D=3.1&cubeTimeFrame.startYear=2024&cubeTimeFrame.endYear=2024&referencePeriods=20240101%2C20240101

    2 Government of New Brunswick. (2023). Agriculture & agri‑food review 2022 (NZ‑00989). https://www2.gnb.ca/content/dam/gnb/Departments/10/pdf/Publications/Agr/review-agriculture-2022.pdf

    3 Agriculture and Agri-Food Canada. Overview of Canada's agriculture and agri-food sector. https://agriculture.canada.ca/en/sector/overview?utm_source

    4 Statistics Canada. (2025, February 28). Farm cash receipts of selected commodities, Canada: January–December 2024 (Table 1) [Data table]. Government of Canada. https://www150.statcan.gc.ca/n1/daily-quotidien/250228/t001d-eng.htm

    5 Prohibition Partners. (2022). The Global Cannabis Report: 3rd Edition [Industry report]. https://prohibitionpartners.com/reports/the-global-cannabis-report-edition-3/

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250902906425/en/

    For Media enquiries:



    Mark McKay – Director of Communications

    [email protected]

    Get the next $OGI alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OGI

    DatePrice TargetRatingAnalyst
    7/17/2024Speculative Buy
    Canaccord Genuity
    4/15/2024Neutral → Buy
    Alliance Global Partners
    1/13/2023Hold → Buy
    Stifel
    1/12/2022Hold → Speculative Buy
    Canaccord Genuity
    1/12/2022$5.70 → $5.30Overweight
    Cantor Fitzgerald
    12/8/2021$5.50 → $5.70Overweight
    Cantor Fitzgerald
    More analyst ratings

    $OGI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Organigram Global Releases Landmark Report: Legal Cannabis Added $16B to Canada's GDP in 2024

    New analysis shows cannabis as a national growth engine, aligning with Prime Minister Carney's One Canadian Economy vision. Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), Canada's largest cannabis company by market share, today released "High Impact, Green Growth: The Economic Footprint of Canada's Cannabis Industry," a national report done in partnership with the Business Data Lab at the Canadian Chamber of Commerce. The report, which examined figures for 2024, underscores the legal cannabis sector's role as a major driver of jobs, economic growth, and innovation, highlighting why it should be included as a pillar of Prime Minister Mark Carney's One Canadian Economy vision. This press r

    9/2/25 6:00:00 AM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organigram Reports Record Third Quarter Fiscal 2025 Results

    Second consecutive quarter of record revenue, strong adjusted EBITDA growth, Free Cash Flow, and continued international expansion Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), Canada's #1 cannabis company by market share1, is pleased to announce its record results for the third quarter ended June 30, 2025 ("Q3 Fiscal 2025" or "Q3"). Q3 FISCAL 2025 HIGHLIGHTS Record Gross Revenue: $110.2 million (+73% year-over-year, +7.2% sequential). Record Net Revenue: $70.8 million (+72% year-over-year, +7.9% sequential). International Revenue: $7.4 million (+208% year-over-year, +21% sequential). Adjusted EBITDA2: $5.7 million (+64% year-over-year, +16%

    8/13/25 6:00:00 AM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organigram to Report Third Quarter Fiscal 2025 Results on August 13, 2025

    Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), Canada's #1 cannabis company by market share, announced today it will report earnings results for its third quarter fiscal 2025 ended June 30, 2025, on Wednesday, August 13, 2025, prior to market open. The Company will host a conference call to discuss its results with details as follows: Date: Wednesday, August 13, 2025 Time: 8:00 am Eastern Time To register for the conference call, please use this link: https://registrations.events/direct/Q4I9676685 To ensure you are connected for the full call, we suggest registering a day in advance or at minimum 10 minutes before the start of the call. After registe

    8/1/25 6:00:00 AM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OGI
    SEC Filings

    View All

    SEC Form 6-K filed by Organigram Global Inc.

    6-K - ORGANIGRAM GLOBAL INC. (0001620737) (Filer)

    9/2/25 2:28:38 PM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Organigram Global Inc.

    6-K - ORGANIGRAM GLOBAL INC. (0001620737) (Filer)

    8/13/25 7:32:51 AM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Organigram Global Inc.

    6-K - ORGANIGRAM GLOBAL INC. (0001620737) (Filer)

    8/1/25 11:46:15 AM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OGI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity resumed coverage on OrganiGram

    Canaccord Genuity resumed coverage of OrganiGram with a rating of Speculative Buy

    7/17/24 12:18:49 PM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OrganiGram upgraded by Alliance Global Partners

    Alliance Global Partners upgraded OrganiGram from Neutral to Buy

    4/15/24 8:40:01 AM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OrganiGram upgraded by Stifel

    Stifel upgraded OrganiGram from Hold to Buy

    1/13/23 7:36:46 AM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OGI
    Financials

    Live finance-specific insights

    View All

    Organigram Reports Record Third Quarter Fiscal 2025 Results

    Second consecutive quarter of record revenue, strong adjusted EBITDA growth, Free Cash Flow, and continued international expansion Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), Canada's #1 cannabis company by market share1, is pleased to announce its record results for the third quarter ended June 30, 2025 ("Q3 Fiscal 2025" or "Q3"). Q3 FISCAL 2025 HIGHLIGHTS Record Gross Revenue: $110.2 million (+73% year-over-year, +7.2% sequential). Record Net Revenue: $70.8 million (+72% year-over-year, +7.9% sequential). International Revenue: $7.4 million (+208% year-over-year, +21% sequential). Adjusted EBITDA2: $5.7 million (+64% year-over-year, +16%

    8/13/25 6:00:00 AM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organigram to Report Third Quarter Fiscal 2025 Results on August 13, 2025

    Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), Canada's #1 cannabis company by market share, announced today it will report earnings results for its third quarter fiscal 2025 ended June 30, 2025, on Wednesday, August 13, 2025, prior to market open. The Company will host a conference call to discuss its results with details as follows: Date: Wednesday, August 13, 2025 Time: 8:00 am Eastern Time To register for the conference call, please use this link: https://registrations.events/direct/Q4I9676685 To ensure you are connected for the full call, we suggest registering a day in advance or at minimum 10 minutes before the start of the call. After registe

    8/1/25 6:00:00 AM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organigram Reports Record Second Quarter Fiscal 2025 Results

    Record gross revenue of $102.8 million and record net revenue of $65.6 million Adjusted EBITDA1 of $4.9 million Net income of $42.5 million Increase in anticipated Motif cost synergies to $15 million from $10 million Total cash position of $83.4 million2 and negligible debt Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), Canada's #1 cannabis company by market share, announced its record results for the second quarter ended March 31, 2025 ("Q2 Fiscal 2025"). The Q2 Fiscal 2025 results include a full quarter of consolidated financials from the Company's acquisition of Motif Labs Ltd. ("Motif") on December 6, 2024. Q2 FISCAL 2025 HIGHLIGHTS Gross r

    5/12/25 6:00:00 AM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OGI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Organigram Holdings Inc.

    SC 13D/A - ORGANIGRAM HOLDINGS INC. (0001620737) (Subject)

    12/10/24 7:10:15 PM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Organigram Holdings Inc.

    SC 13D/A - ORGANIGRAM HOLDINGS INC. (0001620737) (Subject)

    9/3/24 9:30:26 AM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Organigram Holdings Inc. (Amendment)

    SC 13D/A - ORGANIGRAM HOLDINGS INC. (0001620737) (Subject)

    1/25/24 5:23:26 PM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OGI
    Leadership Updates

    Live Leadership Updates

    View All

    Organigram Announces Results of Annual and Special Meeting, including Shareholder Approval of Name Change to Organigram Global Inc.

    Organigram Holdings Inc. ("Organigram" or the "Company") (TSX:OGI) (NASDAQ:OGI) announced today the results of voting at its annual general and special meeting of shareholders (the "Shareholders") held virtually on March 24, 2025 (the "Meeting"). Shareholder Approval of the Name Change and Articles of Amendment At the Meeting, a special resolution approving an amendment to the articles of the Company to change the name of the Company to "Organigram Global Inc." (the "Name Change"), was approved by the affirmative vote of 95.778% of the votes represented at the Meeting. The Name Change remains subject to regulatory approvals, including the approval of the TSX. The TSX has conditionally ap

    3/24/25 8:30:00 PM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organigram Announces Appointment of Craig Harris to Board of Directors

    Organigram Holdings Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), a leading licensed producer of cannabis, announced the appointment of Craig Harris to the Organigram Board of Directors effective today. Craig brings over 20 years of experience as a commercial lawyer, with a background in private practice and legal and regulatory engagement roles for various corporations. He is currently the Assistant General Counsel – Corporate & Commercial Legal at British American Tobacco plc (BAT). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240729497569/en/Craig Harris (Photo: Business Wire) "We are thrilled to welcome Cra

    7/29/24 6:00:00 AM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organigram Announces Appointment of Karina Gehring to Board of Directors

    Organigram Holdings Inc. ("Organigram" or the "Company") (TSX:OGI) (NASDAQ:OGI), announced the appointment of Karina Gehring to the Organigram Board of Directors at the Company's annual general and special meeting held on January 18, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240119151071/en/Karina Gehring (Photo: Business Wire) "We are thrilled to welcome Karina to our Board of Directors. Her extensive expertise in marketing and brand management combined with her ongoing experience with BAT will be a tremendous asset to our Board," said Peter Amirault, Board Chair, Organigram. Karina is one of two directors (includi

    1/19/24 6:00:00 AM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care